MedTrace Logo

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma

NCT05595473 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2024-11-04

No results posted yet for this study

Summary

This is first in human study to evaluate the safety, tolerability, immunogenicity, and preliminary clinical activity of RZ-001 when given to subjects with human telomerase reverse transcriptase (hTERT)-positive HCC.

Conditions

Interventions

DRUG

RZ-001 Dose 1

RZ-001 Dose 1 and VGCV

DRUG

RZ-001 Dose 2

RZ-001 Dose 2 and VGCV

DRUG

RZ-001 Dose 3

RZ-001 Dose 3 and VGCV

DRUG

RZ-001 Dose 4

RZ-001 Dose 4 and VGCV

Sponsors & Collaborators

  • Rznomics, Inc.

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-29
Primary Completion
2029-03-31
Completion
2029-05-31
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05595473 on ClinicalTrials.gov